{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:19:54Z","timestamp":1774325994409,"version":"3.50.1"},"reference-count":67,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL). To determine the optimal dose of MTX in childhood relapsed ALL, the ALL Relapse Berlin-Frankfurt-M\u00fcnster (ALL-REZ BFM) Study Group performed this prospective randomized study. A total of 269 children with a first early\/late isolated (n = 156) or combined (n = 68) bone marrow or any isolated extramedullary relapse (n = 45) of precursor B-cell (PBC) ALL (excluding very early marrow relapse within 18 months after initial diagnosis) were registered at the ALL-REZ BFM90 trial and randomized to receive methotrexate infusions at either 1 g\/m2 over 36 hours (intermediate dose, ID) or 5 g\/m2 over 24 hours (high dose, HD) during 6 (or 4) intensive polychemotherapy courses. Intensive induction\/consolidation therapy was followed by cranial irradiation, and by conventional-dose maintenance therapy. Fifty-five children received stem-cell transplants. At a median follow-up of 14.1 years, the 10-year event-free survival probability was .36 (\u00b1 .04) for the ID group (n = 141), and .38 (\u00b1 .04) for the HD group (n = 128, P = .919). The 2 groups did not differ in terms of prognostic factors and other therapeutic parameters. In conclusion, methotrexate infusions at 5 g\/m2 per 24 hours, compared with 1 g\/m2 per 36 hours, are not associated with increased disease control in relapsed childhood PBC acute lymphoblastic leukemia.<\/jats:p>","DOI":"10.1182\/blood-2007-07-102525","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T04:34:03Z","timestamp":1198038843000},"page":"2573-2580","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"111","author":[{"given":"Arend","family":"von Stackelberg","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Berlin (Charit\u00e9 Universit\u00e4tsmedizin Berlin), Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Berlin (Charit\u00e9 Universit\u00e4tsmedizin Berlin), Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"B\u00fchrer","sequence":"additional","affiliation":[{"name":"Basel University Children's Hospital, Basel, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Fengler","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Berlin (Charit\u00e9 Universit\u00e4tsmedizin Berlin), Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gritta","family":"Janka-Schaub","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Hamburg, Hamburg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Reiter","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Giessen, Giessen, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Mann","sequence":"additional","affiliation":[{"name":"St Anna Kinderspital, Department of Pediatric Hematology\/Oncology, Vienna, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"The Pediatric Clinic II, The University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ratei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Tumor Immunology, Robert-Roessle-Clinic at the HELIOS Klinikum Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Frankfurt, Frankfurt, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Henze","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, University of Berlin (Charit\u00e9 Universit\u00e4tsmedizin Berlin), Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111905182963700_B1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM Group.","volume":"78","author":"Henze","year":"1991","journal-title":"Blood"},{"key":"2019111905182963700_B2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood.V81.3.602.602","article-title":"Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.","volume":"81","author":"Sadowitz","year":"1993","journal-title":"Blood"},{"key":"2019111905182963700_B3","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/blood.V83.12.3468.3468","article-title":"Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia.","volume":"83","author":"B\u00fchrer","year":"1994","journal-title":"Blood"},{"key":"2019111905182963700_B4","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.1996.14.10.2812","article-title":"Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome.","volume":"14","author":"B\u00fchrer","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B5","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87.","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B6","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1166::AID-CNCR29>3.0.CO;2-W","article-title":"Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: A Pediatric Oncology Group study.","volume":"88","author":"Buchanan","year":"2000","journal-title":"Cancer"},{"key":"2019111905182963700_B7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V88.3.831.831","article-title":"Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.","volume":"88","author":"Rivera","year":"1996","journal-title":"Blood"},{"key":"2019111905182963700_B8","first-page":"374","article-title":"Chemotherapy for relapsed childhood acute lymphoblastic leukemia: results of the BFM Study Group.","volume":"36","author":"Henze","year":"1994","journal-title":"Haematol Blood Transfus"},{"key":"2019111905182963700_B9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2141.1997.4413253.x","article-title":"ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.","volume":"99","author":"Giona","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111905182963700_B10","first-page":"500","article-title":"Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials.","volume":"33","author":"B\u00fchrer","year":"1990","journal-title":"Haematol Blood Transfus"},{"key":"2019111905182963700_B11","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.1999.17.12.3745","article-title":"Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study.","volume":"17","author":"Ritchey","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2141.2000.01891.x","article-title":"The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study.","volume":"108","author":"Lawson","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111905182963700_B13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.1992.10.4.624","article-title":"Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.","volume":"10","author":"Wofford","year":"1992","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B14","first-page":"647","article-title":"Similar outcome on boys with isolated and combined testicular acute lymphoblastic leukemia relapse after stratified BFM salvage therapy.","volume":"38","author":"Wolfrom","year":"1997","journal-title":"Haematol Blood Transfus"},{"key":"2019111905182963700_B15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/adc.76.3.190","article-title":"Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia.","volume":"76","author":"Grundy","year":"1997","journal-title":"Arch Dis Child"},{"key":"2019111905182963700_B16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1","article-title":"Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse: the Children's Cancer Group Experience.","volume":"82","author":"Gaynon","year":"1998","journal-title":"Cancer"},{"key":"2019111905182963700_B17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199411103311902","article-title":"Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.","volume":"331","author":"Barrett","year":"1994","journal-title":"N Engl J Med"},{"key":"2019111905182963700_B18","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V78.10.2780.2780","article-title":"Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.","volume":"78","author":"Dopfer","year":"1991","journal-title":"Blood"},{"key":"2019111905182963700_B19","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V101.10.3835","article-title":"Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.","volume":"101","author":"Borgmann","year":"2003","journal-title":"Blood"},{"key":"2019111905182963700_B20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2141.1998.00676.x","article-title":"Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience: Medical Research Council Working Party on Childhood Leukaemia.","volume":"101","author":"Wheeler","year":"1998","journal-title":"Br J Haematol"},{"key":"2019111905182963700_B21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI118409","article-title":"Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate.","volume":"97","author":"Masson","year":"1996","journal-title":"J Clin Invest"},{"key":"2019111905182963700_B22","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.2003.08.047","article-title":"CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.","volume":"21","author":"Clarke","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/1097-0142(19860901)58:5<1024::AID-CNCR2820580507>3.0.CO;2-V","article-title":"Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse.","volume":"58","author":"Brecher","year":"1986","journal-title":"Cancer"},{"key":"2019111905182963700_B24","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.V78.10.2514.2514","article-title":"Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81\u201301 update).","volume":"78","author":"Niemeyer","year":"1991","journal-title":"Blood"},{"key":"2019111905182963700_B25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(95)90164-7","article-title":"Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X: Medical Research Council Working Party on Childhood Leukaemia.","volume":"345","author":"Chessells","year":"1995","journal-title":"Lancet"},{"key":"2019111905182963700_B26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.1996.14.3.911","article-title":"High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.","volume":"14","author":"Veerman","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B27","first-page":"150","article-title":"Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X.","volume":"6","author":"Pui","year":"1992","journal-title":"Leukemia"},{"key":"2019111905182963700_B28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1096-911X(199607)27:1<15::AID-MPO4>3.0.CO;2-X","article-title":"Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.","volume":"27","author":"Lange","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"2019111905182963700_B29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1993.11.5.827","article-title":"Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.","volume":"11","author":"Wolfrom","year":"1993","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1991.9.1.145","article-title":"Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study.","volume":"9","author":"Ochs","year":"1991","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.1992.10.5.810","article-title":"The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia.","volume":"10","author":"Waber","year":"1992","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B32","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.1995.13.10.2490","article-title":"Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice.","volume":"13","author":"Waber","year":"1995","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B33","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL).","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"2019111905182963700_B34","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.V87.4.1532.bloodjournal8741532","article-title":"Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts: BFM Relapse Study Group.","volume":"87","author":"Beyermann","year":"1996","journal-title":"Blood"},{"key":"2019111905182963700_B35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","article-title":"Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Munster.","volume":"14","author":"Schrappe","year":"2000","journal-title":"Leukemia"},{"key":"2019111905182963700_B36","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/sj.leu.2401974","article-title":"Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.","volume":"14","author":"Harms","year":"2000","journal-title":"Leukemia"},{"key":"2019111905182963700_B37","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111905182963700_B38","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","article-title":"Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.","volume":"260","author":"Allegra","year":"1985","journal-title":"J Biol Chem"},{"key":"2019111905182963700_B39","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1074\/jbc.270.14.7842","article-title":"Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells.","volume":"270","author":"Spinella","year":"1995","journal-title":"J Biol Chem"},{"key":"2019111905182963700_B40","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V80.5.1316.1316","article-title":"Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.","volume":"80","author":"Whitehead","year":"1992","journal-title":"Blood"},{"key":"2019111905182963700_B41","doi-asserted-by":"crossref","first-page":"15356","DOI":"10.1016\/S0021-9258(19)49541-0","article-title":"Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells: definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds.","volume":"267","author":"Barrueco","year":"1992","journal-title":"J Biol Chem"},{"key":"2019111905182963700_B42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V89.3.1013","article-title":"Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.","volume":"89","author":"Gorlick","year":"1997","journal-title":"Blood"},{"key":"2019111905182963700_B43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V86.2.677.bloodjournal862677","article-title":"Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.","volume":"86","author":"Goker","year":"1995","journal-title":"Blood"},{"key":"2019111905182963700_B44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V90.2.578","article-title":"Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.","volume":"90","author":"Matherly","year":"1997","journal-title":"Blood"},{"key":"2019111905182963700_B45","first-page":"2149","article-title":"Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.","volume":"48","author":"Pizzorno","year":"1988","journal-title":"Cancer Res"},{"key":"2019111905182963700_B46","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V93.5.1677.405a16_1677_1683","article-title":"Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.","volume":"93","author":"Rots","year":"1999","journal-title":"Blood"},{"key":"2019111905182963700_B47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2141.2000.02071.x","article-title":"Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia.","volume":"109","author":"Rots","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111905182963700_B48","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","article-title":"In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia.","volume":"86","author":"Klumper","year":"1995","journal-title":"Blood"},{"key":"2019111905182963700_B49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s004320050310","article-title":"Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.","volume":"125","author":"Weigand","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019111905182963700_B50","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","article-title":"High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.","volume":"20","author":"Sk\u00e4rby","year":"2006","journal-title":"Leukemia"},{"key":"2019111905182963700_B51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0014-2964(72)90125-9","article-title":"Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.","volume":"8","author":"Goldie","year":"1972","journal-title":"Eur J Cancer"},{"key":"2019111905182963700_B52","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/10428190600942769","article-title":"Very high-dose methotrexate (33.6 g\/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute\/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.","volume":"47","author":"Nathan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2019111905182963700_B53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1385\/1-59259-307-0:339","article-title":"Rationale for high-dose methotrexate in childhood acute lymphoblastic leukemia.","volume-title":"Treatment of Acute Leukemias New Directions for Clinical Research","author":"Brenner","year":"2002"},{"key":"2019111905182963700_B54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"2019111905182963700_B55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect.","volume":"314","author":"Evans","year":"1986","journal-title":"N Engl J Med"},{"key":"2019111905182963700_B56","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood.V94.9.3121.421k08_3121_3128","article-title":"Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.","volume":"94","author":"Rots","year":"1999","journal-title":"Blood"},{"key":"2019111905182963700_B57","first-page":"S124","article-title":"Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.","volume":"83","author":"Pui","year":"2004","journal-title":"Ann Hematol"},{"key":"2019111905182963700_B58","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity.","volume":"12","author":"Relling","year":"1994","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B59","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.1997.15.5.2125","article-title":"Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.","volume":"15","author":"Widemann","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B60","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer"},{"key":"2019111905182963700_B61","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/sj.leu.2401098","article-title":"Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.","volume":"12","author":"Rubnitz","year":"1998","journal-title":"Leukemia"},{"key":"2019111905182963700_B62","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2006.05.9055","article-title":"Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.","volume":"24","author":"Spiegler","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111905182963700_B63","first-page":"1263","article-title":"Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.","volume":"26","author":"Reddick","year":"2005","journal-title":"Am J Neuroradiol"},{"key":"2019111905182963700_B64","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mpo.2950250503","article-title":"Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).","volume":"25","author":"Schroeder","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"2019111905182963700_B65","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","article-title":"Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.","volume":"358","author":"Eckert","year":"2001","journal-title":"Lancet"},{"key":"2019111905182963700_B66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/1-59259-307-0:199","article-title":"Treatment of relapsed acute lymphoblastic leukemia.","volume-title":"Treatment of Acute Leukemias New Directions for Clinical Research","author":"Henze","year":"2002"},{"key":"2019111905182963700_B67","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/5\/2573\/486358\/zh800508002573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/5\/2573\/486358\/zh800508002573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:55:46Z","timestamp":1630364146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/5\/2573\/109926\/Highdose-compared-with-intermediatedose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-102525","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}